Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model.
Adult
Antimalarials
/ administration & dosage
Birth Weight
Demography
Drug Combinations
Female
Fetal Macrosomia
Ghana
/ epidemiology
Humans
Infant, Low Birth Weight
Malaria
/ prevention & control
Models, Statistical
Pregnancy
Pregnancy Complications, Parasitic
/ prevention & control
Pyrimethamine
/ administration & dosage
Sulfadoxine
/ administration & dosage
Generalized ordered partial proportional odds model
Low birth weight
Macrosomia
Normal birth weight
Predictive probability
Pregnant women
Sulphadoxine-pyrimethamine
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
19 Mar 2022
19 Mar 2022
Historique:
received:
28
05
2021
accepted:
10
03
2022
entrez:
20
3
2022
pubmed:
21
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Low birth weight is a public health problem in Africa with the cause attributable to malaria in pregnancy. World Health Organization recommends the use of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine to prevent malaria during pregnancy. The objective of this study was to evaluate the prevalence and trajectories of birth weight and the direct impact and relationship between sulfadoxine-pyrimethamine and birth weight in Ghana since 2003. This study used secondary data obtained from the Demographic and Health Survey conducted in Ghana since 2003. Low birth weight was defined as weight < 2500 g irrespective of the gestational age of the foetus, while normal birth weight was between 2500 g to < 4000 g and macrosomia was = > 4000 g. In all the analysis, we adjusted for clustering, stratification and weighting to reduce bias and improve precision of the estimates. Analysis was performed on each survey year as well as the pooled dataset. The generalized ordered partial proportional odds model was used due to violations of the parallel regression model assumptions. Efforts were made to identify all confounding variables and these were adjusted for. Predictive analysis was also executed. The overall prevalence of low birth weight was 9% while that of macrosomia was 13%. The low birth weight for 2003 was 12% while in 2008 it was 21% and then 68% in 2014. The mean birth weight of the children in 2014 was 3.16 (3.14, 3.19), 2008 was 3.37 (3.28, 3.45) and 2003 was 3.59 (3.49, 3.69) while that of the pooled data was 3.28 (3.25, 3.30). The adjusted model (taking into consideration all confounding variables) showed that non-uptake of SP could result in 51% odds of giving birth to a low-birth-weight compared with normal birth weight child. An insignificant result was observed between macrosomia and low birth weight. There is higher probability that low birth weight could increase over the next couple of years if measures are not taking to reverse the current trajectories. The uptake of sulfadoxine-pyrimethamine should continue to be encouraged and recommended because it has a direct beneficial effect on the weight of the child.
Sections du résumé
BACKGROUND
BACKGROUND
Low birth weight is a public health problem in Africa with the cause attributable to malaria in pregnancy. World Health Organization recommends the use of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine to prevent malaria during pregnancy. The objective of this study was to evaluate the prevalence and trajectories of birth weight and the direct impact and relationship between sulfadoxine-pyrimethamine and birth weight in Ghana since 2003.
METHOD
METHODS
This study used secondary data obtained from the Demographic and Health Survey conducted in Ghana since 2003. Low birth weight was defined as weight < 2500 g irrespective of the gestational age of the foetus, while normal birth weight was between 2500 g to < 4000 g and macrosomia was = > 4000 g. In all the analysis, we adjusted for clustering, stratification and weighting to reduce bias and improve precision of the estimates. Analysis was performed on each survey year as well as the pooled dataset. The generalized ordered partial proportional odds model was used due to violations of the parallel regression model assumptions. Efforts were made to identify all confounding variables and these were adjusted for. Predictive analysis was also executed.
RESULTS
RESULTS
The overall prevalence of low birth weight was 9% while that of macrosomia was 13%. The low birth weight for 2003 was 12% while in 2008 it was 21% and then 68% in 2014. The mean birth weight of the children in 2014 was 3.16 (3.14, 3.19), 2008 was 3.37 (3.28, 3.45) and 2003 was 3.59 (3.49, 3.69) while that of the pooled data was 3.28 (3.25, 3.30). The adjusted model (taking into consideration all confounding variables) showed that non-uptake of SP could result in 51% odds of giving birth to a low-birth-weight compared with normal birth weight child. An insignificant result was observed between macrosomia and low birth weight.
CONCLUSION
CONCLUSIONS
There is higher probability that low birth weight could increase over the next couple of years if measures are not taking to reverse the current trajectories. The uptake of sulfadoxine-pyrimethamine should continue to be encouraged and recommended because it has a direct beneficial effect on the weight of the child.
Identifiants
pubmed: 35305604
doi: 10.1186/s12884-022-04565-7
pii: 10.1186/s12884-022-04565-7
pmc: PMC8933913
doi:
Substances chimiques
Antimalarials
0
Drug Combinations
0
fanasil, pyrimethamine drug combination
37338-39-9
Sulfadoxine
88463U4SM5
Pyrimethamine
Z3614QOX8W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
223Informations de copyright
© 2022. The Author(s).
Références
J Infect Dis. 1999 Dec;180(6):1987-93
pubmed: 10558956
Cad Saude Publica. 2017 Sep 28;33(9):e00203615
pubmed: 28977284
Biochem Soc Trans. 1999 Aug;27(4):478-82
pubmed: 10917625
Ann Hum Biol. 1997 Nov-Dec;24(6):547-55
pubmed: 9395740
Trop Med Int Health. 2001 Oct;6(10):770-8
pubmed: 11679125
Prev Med. 2019 Jan;118:196-204
pubmed: 30342108
Reprod Health. 2019 May 29;16(1):70
pubmed: 31142327
JAMA. 2013 Feb 13;309(6):594-604
pubmed: 23403684
Placenta. 2004 May;25(5):359-78
pubmed: 15081631
J Infect Dis. 2000 May;181(5):1740-5
pubmed: 10823776
Am J Trop Med Hyg. 2003 Dec;69(6):574-81
pubmed: 14740871
Eur J Clin Nutr. 2000 Mar;54(3):247-52
pubmed: 10713748
Sci Rep. 2019 Dec 13;9(1):19034
pubmed: 31836735
Int J Gynaecol Obstet. 2009 Mar;104 Suppl 1:S11-3
pubmed: 19154995
BMC Public Health. 2011 Oct 20;11:818
pubmed: 22011362
Exp Parasitol. 2006 May;113(1):36-42
pubmed: 16430888
Ann Trop Med Parasitol. 2000 Jan;94(1):7-13
pubmed: 10723519
Ghana Med J. 2010 Jun;44(2):64-9
pubmed: 21327006
Am J Trop Med Hyg. 2003 Jan;68(1):115-9
pubmed: 12556159
BJOG. 2016 Sep;123(10):1589-92
pubmed: 26629786
Matern Health Neonatol Perinatol. 2018 Aug 08;4:15
pubmed: 30094052
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451
Front Psychol. 2019 Sep 06;10:1942
pubmed: 31551853
PLoS Med. 2017 Feb 28;14(2):e1002243
pubmed: 28245259
Ann Glob Health. 2019 Dec 17;85(1):147
pubmed: 31871910
Lancet. 2013 Feb 9;381(9865):476-83
pubmed: 23290494